Gerald Mancuso, MD
Interventional Cardiology · Kansas City, MONPI 1427012574
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $355,085 of the $401,779 with a category attached, or 88.4%. 56 manufacturers reported payments, led by Boehringer Ingelheim at 36.0% of the total. Reporting peaked in 2019 at $88,597 and has fallen 74.8% since, to $22,287 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,575 payments — averaging $255.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$145K
- Amgen$99K
- Lilly USA, LLC$72K
- Esperion Therapeutics, Inc.$52K
- Amarin Pharma, Inc.$20K
- Boston Scientific$2K
- plus $13K from 50 others
What the payments were for
- Consulting fees$11,5503%
- Speaking & faculty fees$355,08588%
- Travel & lodging$12,0813%
- Food & beverage$23,0136%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$208,232
- Repatha$95,372
- NEXLIZET$51,683
- NEXLETOL$51,683
- Vascepa$18,851
- RESOLUTE ONYX$284
- Resolute$253
- INJECTAFER$245
- LOKELMA$241
- XARELTO$229
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$228
- CAMZYOS$227
- Xience Sierra Coronary Stent System$164
- AMVUTTRA$150
- Optis Coronary Imaging System$147
- Kerendia$135
- OPTIS$131
- WATCHMAN FLX$129
- VYNDAQEL$127
- UPTRAVI$125
How this compares
$401,779 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 693 | $809,416 |
| EliquisApixaban | 447 | $521,663 |
| Repatha SureclickEvolocumab | 242 | $282,376 |
| JardianceEmpagliflozin | 145 | $168,857 |
| Nebivolol Hcl | 988 | $61,526 |
| LivaloPitavastatin Calcium | 47 | $37,990 |
| Praluent PenAlirocumab | 30 | $36,099 |
| VascepaIcosapent Ethyl | 38 | $34,645 |
| EntrestoSacubitril/Valsartan | 20 | $28,884 |
| Ezetimibe | 1,309 | $28,051 |
| Olmesartan Medoxomil | 1,214 | $23,926 |
| Rosuvastatin Calcium | 2,020 | $22,821 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $16,840 |
| Metoprolol Succinate | 1,242 | $14,242 |
| Atorvastatin Calcium | 1,424 | $14,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $1,282 | $809,416693 claims |
| PfizerEliquis | $1,010 | $521,663447 claims |
| Boehringer IngelheimJardiance | $144,809 | $168,857145 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $858 | $37,99047 claims |
| NovartisEntresto | $1,330 | $28,88420 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $30 | $20,32035 claims |
| Esperion Therapeutics, Inc.Nexlizet | $52,063 | $16,84021 claims |
| Daiichi Sankyo Inc.Savaysa | $335 | $8,15712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Kansas City
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Adnan ChhatriwallaKansas City$114K
- Kenneth HuberKansas City$110K
- Chetan HudedKansas City$61K
- Adam SalisburyKansas City$52K
- Steven MarsoKansas City$42K
- Dany JacobKansas City$35K
- Muhammad Anis HaiderKansas City$35K
- Francisco LammogliaKansas City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.